CCCC C4 Therapeutics, Inc.

NASDAQ
$4.24

C4 Therapeutics, Inc. (CCCC) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +10.4% since its last earnings release on August 11, 2026.

C4 Therapeutics Beat Consensus Estimates
Tuesday, August 11, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.21)
Rev est $9.1M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.04

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About C4 Therapeutics, Inc.

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc. is based in WATERTOWN, Mass.

Sector

Healthcare

Industry

Biotechnology